Cerylid regroups, lays off staff
Thursday, 04 September, 2003
Unlisted Melbourne company Cerylid Biosciences has reorganised, necessitating the layoff of a portion of its staff.
But management at the natural products drug discovery company was quick to reassure Australian Biotechnology News that the strategy is not a sign of trouble for the company, but rather a step taken to realign the needs of the business.
"The reorganisation is due to a realignment of projects, and the company's needs going forward," said Cerylid CEO Dr Jackie Fairley.
"Like many in the sector, we're keeping an eye on cash burn, but we're in a strong cash position, with two years of cash available."
$96m RNA Research and Manufacturing Facility opens in NSW
The new 4500 sqm RNA Research and Manufacturing Facility within the Macquarie University...
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
